Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathol...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 2,157
- Institution
- Shanghai Cancer Institute
External Links
Identifiers
- ORCID
- 0000-0001-8833-7262
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.